B-Vitamin Treatment Trialists‘ Collaboration (2006) Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 151: 282–287CrossRefGoogle Scholar

Bazzano LA, Reynolds K, Holder KN, He J (2006) Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 296: 2720–2726PubMedCrossRefGoogle Scholar

Boushey CJ, Beresford SA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274: 1049–1057PubMedCrossRefGoogle Scholar

Dentali F, Gianni M, Ageno W (2007) Folic acid supplementation and cardiovascular diseases. JAMA 297: 1549–1550; author reply 1550PubMedCrossRefGoogle Scholar

Lange H, Suryapranata H, De Luca G et al. (2004) Folate therapy and in-stent restenosis after coronary stenting. New Engl J Med 350: 2673–2681PubMedCrossRefGoogle Scholar

McCully KS (1969) Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111–128PubMedGoogle Scholar

Schnyder G, Roffi M, Pin R et al. (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. New Engl J Med 345: 1593–1600PubMedCrossRefGoogle Scholar

Toole JF, Malinow MR, Chambless LE et al. (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291: 565–575PubMedCrossRefGoogle Scholar

Yang Q, Botto LD, Erickson JD et al. (2006) Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113: 1335–1343PubMedCrossRefGoogle Scholar